On May 11th 2011, during BioForum (which will take place in Lodz at andel’s Hotel) you will have an opportunity to take part in the lecture conducted by one of the experts in biotechnology. Dr Thomas F. Zionchek will share his experiences related with functioning of the world’s largest biotechnological company producing monoclonal antibodies. Moreover, he is responsible for licensing therapies and technologies in various medical branches like ophthalmology and neurology. These branches developed by Polish and Central European biotechnological companies are in the center of Genentech’s attention.
I could discuss the founding of Genentech (the first Biotech company), the innovative medicines and contributions we have made over the years, and our current scientific focus and relationship with Roche- Dr Thomas F. Zioncheck describes his future plans.
Genentech is only one from many more companies, which are interested in partnership with Central European market of innovative biotechnology. Presence of companies like Roche, Merck MSD or AstraZeneca is a clear evidence that leaders of world’s biotechnology don’t neglect potential which lies in this region.
Ten years ago, nobody dreamed that in Poland will come time for development of modern biotechnology. The development based on the latest academic achievements in biology and medicine which we observed in last 3-4 years. In this period various companies like Mabion S.A., Celther sp. z o.o., Eurimplant S.A., Blirt S.A., Proteon Pharmaceuticals sp. z o.o. began their dynamic work. Characteristic feature of these companies is the fact that their work is concentrating on the implementation of innovative biotechnological products. Furthermore, these companies have expanded R&D sections and employed prominent scientists.
One of the core catalyst of this process is BioForum - Central European Forum of Biotechnology and Innovative Biobusiness organized by Bio-Tech Consulting Sp. Z o.o. This meeting is a great place not only to make new contacts among scientists and innovative biobusiness representatives, but it is also an opportunity to create network amid Central European biotechnological companies.
Creation of such network is very crucial, because Central European countries like Poland, Czech Republic, Hungary or Slovakia face the same problems and challenges – they have to catch up with other regions due to 45 years of communistic enslavement. That period had very negative impact not only on the development of modern economy but also on the mental side of the oppressed societies. Joining strengths in biotechnology will make this region a very interesting partner for world leaders in this sector. Speaking separately means that gaining noticeable position in this very competitive sector of economy will take more time for companies and for the smaller one it will be almost unattainable.
Common actions will stimulate boom of cooperation among companies in Central Europe and let gain more funds from European Union to develop innovative economy by its acceleration. Furthermore, this will make Central European companies more competitive in relation to West European and American counterparts.
BioForum 2011 as the most important event in biosector of Central Europe is a great source for new ideas, products and innovative medicines, including the biotechnological ones. Moreover, BioForum gives great opportunities to make new contacts with Polish and Central European leaders in biotechnology.
